Newsroom
Featured News
Image
Patient Voices
Explore Yajaira's journey with severe hypertriglyceridemia (sHTG), including the risks of high triglycerides, pancreatitis, and the importance of early awareness.
People & Impact
Explore Ionis' 2025 Corporate Responsibility Report — covering RNA-targeted medicine breakthroughs, ESG commitments, employee impact, and sustainability milestones.
Image
Patient Voices
March marks Amyloidosis Awareness Month. We sat down with Charles, an 88-year-old retired cardiologist from Massachusetts, who shared what it’s like to diagnose and treat heart disease for decades and then face a diagnosis himself. His experience with transthyretin amyloid cardiomyopathy (ATTR-CM) offers a unique perspective on this underrecognized condition.
Image
Defining Moments
2025 was a defining year for Ionis, hallmarked by our first two independent launches as a commercial stage biotech company. Now, Ionis is poised for another transformative year - at JPM 2026 we shared highlights from the past year and outlined key anticipated milestones.
Image
Recent posts
Image
Patient Voices
Living with an Invisible Illness: Yajaira’s Journey with Severe Hypertriglyceridemia (sHTG)
Image
People & Impact
Our 2025 Corporate Responsibility Report: Building Momentum for Better Futures
Image
Patient Voices
From Treating ATTR-CM to Living with It: A Conversation with a Cardiologist
Image
Defining Moments
Ionis JPM 2026 Takeaways: Breakthrough Therapies Driving Accelerating Growth
Image
Patient Voices
Behind the Mystery of Angelman Syndrome: A Journey of Resilience and Strength
Image
Patient Voices
Meet Rick: Navigating Life with Familial Chylomicronemia Syndrome (FCS)
Image
Image
People & Impact
Ionis CEO Brett Monia, Ph.D Receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
Image
Sign up for investor news alerts
For the latest on Ionis investor news.